NCT06300450 Randomized Controlled Trial of Alert-Based Computerized Decision Support for Patients With Peripheral Artery Disease Not Prescribed Lipid-Lowering Therapy
| NCT ID | NCT06300450 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Brigham and Women's Hospital |
| Condition | Peripheral Artery Disease |
| Study Type | INTERVENTIONAL |
| Enrollment | 400 participants |
| Start Date | 2023-03-01 |
| Primary Completion | 2026-12-28 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 400 participants in total. It began in 2023-03-01 with a primary completion date of 2026-12-28.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
This single-center, 400-patient, randomized controlled trial assesses the impact of a patient- and provider-facing EPIC Best Practice Advisory (BPA; alert-based computerized decision support tool) to increase guideline-directed utilization of statin and statin-alternative oral LDL-C lowering therapies in patients with PAD who are not being prescribed LDL-C-lowering therapy.
Eligibility Criteria
Inclusion Criteria: * All patients ≥ 18 years old * Seen in Cardiovascular Medicine Clinic, Primary Care, Podiatry, Vascular Surgery, and Diabetology * Medical history entry, visit diagnosis, or problem list entry of PAD * Not prescribed LDL-C-lowering therapy Exclusion Criteria: * Patients taking a statin, ezetimibe, bempedoic acid, a PCSK9 inhibitor, inclisiran or a combination will be excluded
Contact & Investigator
Gregory Piazza
PRINCIPAL INVESTIGATOR
BWH
Frequently Asked Questions
Who can join the NCT06300450 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Peripheral Artery Disease. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06300450 currently recruiting?
Yes, NCT06300450 is actively recruiting participants. Contact the research team at gpiazza@bwh.harvard.edu for enrollment information.
Where is the NCT06300450 trial being conducted?
This trial is being conducted at Boston, United States.
Who is sponsoring the NCT06300450 clinical trial?
NCT06300450 is sponsored by Brigham and Women's Hospital. The principal investigator is Gregory Piazza at BWH. The trial plans to enroll 400 participants.